Previous 10 | Next 10 |
2024-02-20 11:19:26 ET More on Repligen Repligen: Hard To Justify Stock's Current Valuation Danaher, Repligen rise as German peer Sartorius beats in Q4 Repligen to issue $600M convertible senior notes Seeking Alpha’s Quant Rating on Repligen Hi...
2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...
WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday, February 21, 2024. The Company will issue a press release before the market opens and will host a conference ca...
2024-01-26 12:23:42 ET More on Bio-Rad Labs, Danaher, etc. Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics J.P. Morgan 42nd Annual Healthcare Conference Danaher Corporation (DHR) 42nd Annual JPMorgan Healthcare Conference (Transcript) Thermo...
2024-01-21 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-20 05:00:00 ET Summary NZS Capital is an investment company focused on adaptable, innovative businesses that work toward maximizing non-zero-sum (NZS, or win-win) outcomes for their investors, customers, employees, society, and the global environment. The flagship strategy...
2023-12-24 08:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare conference being held January 8-11 in San Francisco. To...
2023-12-15 16:09:56 ET Summary Today we take a deeper look at Repligen Corporation, a biologic manufacturer whose shares have rallied over 50% since late October. The rally seems overextended given both earnings and revenues are tracking to significant declines in FY2023. An a...
2023-12-07 07:57:53 ET More on Repligen Repligen Corporation (RGEN) Q3 2023 Earnings Call Transcript Repligen: Current Market Values Well Supported, Valuations Are Not, Reiterate Hold Repligen beats top and bottom line estimates, narrows FY guidance Repligen ...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...